Injectable · Hydration · Skin Quality

Skin Boosters

How this page was made
This page was written with AI assistance and reviewed against the sources listed under References below. It is general information only, not medical advice. See our full disclaimer for how SHEA creates and reviews treatment information.
01

What it is

“Skin booster” is a broad term used on aesthetic clinic menus rather than the name of one standardized treatment. Products marketed this way can differ substantially in their ingredients, formulation, intended use, and supporting evidence.

Some skin boosters are based primarily on hyaluronic acid (HA). Others combine HA with materials such as poly-D,L-lactic acid (PDLLA), while polynucleotide (PN) products may also be grouped under the skin-booster category by clinics.

Even HA-based products are not necessarily formulated in the same way. For example, SKINVIVE by Juvéderm contains HA crosslinked with BDDE, while other products marketed as skin boosters may use different HA formulations. Because the category is so broad, ask the clinic for the exact product name rather than relying on the term “skin booster” alone.

02

Products you may see on Korean clinic menus

Volite / SKINVIVE by Juvéderm
Hyaluronic acid
VYC-12L is an injectable HA gel. In the United States it is marketed as SKINVIVE by Juvéderm and is FDA-approved for intradermal injection to improve cheek skin smoothness in adults. The formulation contains HA crosslinked with BDDE and lidocaine.
Juvelook
PDLLA + HA
Juvelook is a Korean injectable product combining poly-D,L-lactic acid (PDLLA) with hyaluronic acid. Its composition and proposed mechanism differ from HA-only injectable products, so evidence for an HA product should not automatically be applied to Juvelook, or vice versa.
Rejuran
Polynucleotide (PN)
Rejuran is a PN-based medical device manufactured by PharmaResearch. It belongs to a different product category from HA and PDLLA-HA injectables. See the PDRN & Polynucleotide page for a closer look at PN and PDRN evidence.
Teosyal Redensity I
HA-based injectable
An HA-based injectable formulation that also contains additional components. Its evidence and regulatory status should be considered separately rather than inferred from studies of other HA products.
Other skin boosters
Product varies
Korean clinics offer many additional products under the skin-booster label. The ingredient, formulation, regulatory status, and clinical evidence can differ between them. Ask for the exact product name before treatment.
03

Why people consider it

  • They are considering injectable treatment aimed at skin hydration, smoothness, or other aspects of skin quality
  • They are interested in an injectable treatment that is not primarily intended to relax facial muscles
  • They want to compare different injectable products that clinics group together under the “skin booster” name
04

What the experience is like

Skin boosters are generally administered through multiple injections across the treatment area. Injection technique, treatment depth, amount used, number of injection points, and treatment schedule depend on the specific product.

Temporary injection-site reactions such as redness, swelling, bruising, tenderness, or small raised areas can occur. The expected recovery period and treatment schedule can also differ between products.

Because “skin booster” covers several different types of injectable treatment, there is no single treatment experience or schedule that should be assumed to apply to every product.

05

Limitations & considerations

  • “Skin booster” does not identify a standardized treatment, so the exact product being injected should be confirmed before treatment
  • Evidence for one product should not automatically be applied to another product marketed under the same skin-booster label
  • HA products, PDLLA-HA products, and PN products have different compositions and supporting evidence
  • Regulatory indications and product status can also differ between countries and between individual products
  • Product-specific contraindications, precautions, and potential adverse effects should be checked for the actual product being used
  • No specific improvement in hydration, smoothness, texture, radiance, or other skin-quality measures can be guaranteed
Evidence note
Clinical evidence should be interpreted product by product rather than for “skin boosters” as a single category. SKINVIVE by Juvéderm has been evaluated in a pivotal clinical study and received US FDA approval for intradermal injection to improve cheek skin smoothness in adults. That evidence applies to the specific VYC-12L formulation and indication and should not be transferred to other HA products.
Published clinical evidence also exists for PDLLA-HA products such as Juvelook, but the studies examine particular treatment areas and protocols. Recent studies include prospective clinical evaluations of PDLLA-HA for facial rejuvenation, the tear-trough area, and nasolabial folds. These studies are generally smaller than the pivotal evidence supporting SKINVIVE, and their findings should not be generalized to every use of Juvelook or to other skin boosters.
Rejuran contains polynucleotide (PN), not PDRN. PN has its own clinical literature and should be evaluated separately from both HA and PDLLA-HA products. The fact that clinics may market all of these treatments as “skin boosters” does not mean that their mechanisms, evidence, or expected outcomes are equivalent.

References

Regulatory information and peer-reviewed literature.

1. US Food and Drug Administration. SKINVIVE by Juvéderm (VYC-12L), P110033/S059 — approval information, indication, composition, and pivotal clinical evidence.
US regulatory · Product-specific evidence
2. Young SM, Lau EKH. Hybrid Biostimulator and Hyaluronic Acid Injectable for Tear Trough Rejuvenation. Aesthetic Plastic Surgery, 2026.
Peer-reviewed · Prospective cohort · PDLLA-HA · Product-specific
3. Seo SB, et al. The Effective Delivery of Poly(D,L-lactic Acid) (Juvelook) via Needle-Free Injection (CUREJET) for Facial Rejuvenation. Aesthetic Plastic Surgery, 2026.
Peer-reviewed · Clinical study · PDLLA · Product-specific
4. Yi KH, Rosellini I, Lim JJM, Kim HS. A Clinical Study on the Efficacy and Safety of Injectable PDLLA for Nasolabial Fold Correction: Juvelook treatment for Nasolabial fold. Journal of Craniofacial Surgery, 2026.
Peer-reviewed · Prospective case series (n=20) · PDLLA-HA · Product-specific
5. PharmaResearch. REJURAN product information — composition: PN (Polynucleotide); intended purpose: temporary improvement of facial wrinkles.
Manufacturer · Product information
Scroll to Top